RxDoctor Payments DataLook up a doctor →

David Gubin, MD

Urology · Memphis, TNNPI 1235164286

Payments from drug & device makers

$1,034,637in general payments, 2019–2025

Across 791 payments — averaging $1308.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Triad Life Sciences Inc.$1M
  • Coloplast$19K
  • Axonics, Inc.$2K
  • Teleflex LLC$1K
  • Boston Scientific$1K
  • Sumitomo Pharma America, Inc.$952
  • plus $7K from 51 others

What the payments were for

  • Consulting fees$3,6000%
  • Travel & lodging$6080%
  • Food & beverage$16,4482%
  • Education$10,2861%
  • Other$1,003,69597%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,034,637 in reported general payments places this provider in the 95th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$732,958
Medicare patients
994
Services billed
85,369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide18$247,546
GemtesaVibegron283$179,546
MyrbetriqMirabegron267$158,480
OrgovyxRelugolix21$54,497
Solifenacin Succinate214$10,853
Tamsulosin Hcl791$8,636
Testosterone Cypionate112$7,412
Oxybutynin Chloride ErOxybutynin Chloride471$6,373
Ciprofloxacin Hcl578$3,398
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen650$3,279
Tolterodine Tartrate ErTolterodine Tartrate16$2,897
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav329$2,677
Testosterone36$2,308
Finasteride147$1,963
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst145$1,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$359$406,026285 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$952$234,043304 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 urology providers in Tennessee.

Other urology in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →